SLDB vs. SOPH, OCGN, CRBU, TNYA, MGTX, JSPR, AURA, TCRX, AVXL, and ADAP
Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include SOPHiA GENETICS (SOPH), Ocugen (OCGN), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), MeiraGTx (MGTX), Jasper Therapeutics (JSPR), Aura Biosciences (AURA), TScan Therapeutics (TCRX), Anavex Life Sciences (AVXL), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.
SOPHiA GENETICS (NASDAQ:SOPH) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Solid Biosciences received 235 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.73% of users gave SOPHiA GENETICS an outperform vote while only 67.47% of users gave Solid Biosciences an outperform vote.
Solid Biosciences has a net margin of 0.00% compared to Solid Biosciences' net margin of -126.63%. Solid Biosciences' return on equity of -47.40% beat SOPHiA GENETICS's return on equity.
SOPHiA GENETICS has higher revenue and earnings than Solid Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
SOPHiA GENETICS has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 19.3% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, SOPHiA GENETICS had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for SOPHiA GENETICS and 1 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.39 beat SOPHiA GENETICS's score of -1.00 indicating that SOPHiA GENETICS is being referred to more favorably in the media.
SOPHiA GENETICS presently has a consensus price target of $8.00, suggesting a potential upside of 65.98%. Solid Biosciences has a consensus price target of $18.25, suggesting a potential upside of 76.50%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe Solid Biosciences is more favorable than SOPHiA GENETICS.
Summary
Solid Biosciences beats SOPHiA GENETICS on 9 of the 17 factors compared between the two stocks.
Get Solid Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solid Biosciences Competitors List
Related Companies and Tools
